GlobeNewsWire
13 Jan 2026, 20:05 UTC · 35w ago
Verdict
Headline leans bearish. We score TVTX −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA extended the review timeline for Travere Therapeutics' supplemental New Drug Application for FILSPARI to April 13, 2026.
So whatRegulatory delays for key drug candidates typically lead to significant valuation drops and deferred revenue expectations.
More negative than 99% of claims this week
Travere Therapeutics shares fell more than 30% in intraday trading on January 13, 2026, leading to a trading halt.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 95% of claims this week
The FDA requested further data to characterize clinical benefit after designating the company's additional responses as a major amendment.
More negative than 91% of claims this week
Law firm Block & Leviton is investigating Travere Therapeutics for potential securities fraud and misleading communications regarding the regulatory timeline.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is under investigation for securities fraud following a 30% stock price drop and an FDA review extension.
More negative than 87% of ticker scores this week
The company is being investigated by a law firm for potentially misleading investors.
More negative than 87% of ticker scores this week
The company is under investigation for possible securities fraud.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
2h ago
+77.2%
Price is moving against the score
$60.41 vs $34.10 close before publication (Jan 12) · not market-adjusted
TVTX chart →